Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 134

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 134
---
. Mr. Noam has extensive experience as a
senior executive, particularly in the agriculture and healthcare sectors, leading teams in the development and execution of commercialization
strategies, driving long-term growth and value-creation for businesses. Mr. Noam holds an MBA from Tel Aviv University and a BSc in Industrial
and Management Engineering from Ben-Gurion University in Beer Sheva, Israel, both graduated with honors.

Dr. Dan Jacob
Gelvanhas served as Chief Executive Officer of AgPlenus Ltd., a subsidiary of Evogene, since February 19, 2024. Between 2019 and
2023, Dr. Gelvan served as Chief Executive Officer at t-syte Ltd., a seed investor operating as an incubator for early-stage digital health
start-ups. Between 2017 and 2023, Dr. Gelvan also served as chairman of the board of directors of Biobeat Ltd., a medical device company
with approved products for remote monitoring of vital signs. Between 2018 and 2019, Dr. Gelvan served as Chief Executive Officer at Tiselia,
a stealth-mode medical device company developing a deep-tech solution for remote treatment and monitoring of patients. From 2017 to 2018
he served as executive vice president of operations at PolyPid Ltd., a drug delivery company. From 2005 to 2017, Dr. Gelvan served as
managing director at Aurum Ventures MKI Ltd., a venture capital firm. From 2004 to 2005, he served as Chief Executive Officer and President,
at Gammacan International Inc., an early-stage immune-oncology company. From 1997 to 2004, he served as Chief Executive Officer and founder
at Zetiq Ltd. and Zetiq Inc., a diagnostic and high-throughput drug discovery company focused on oncology. Dr. Gelvan holds a BA and an
MA degree in Economics from the Hebrew University of Jerusalem and a Ph. D. in Business Economics from Roskilde University of Denmark.

80

Directors

Mr. Nir Nimrodihas served as a director of our Company since he was appointed by the Board in September 2022 and as chairperson since March 2025.
He was a consultant to the Board of our Company from April 2020 until September 2022. Mr. Nimrodi have been the Chairman and Chief Executive
Officer of Accellix Inc, a leading cell therapy analytical company